2018年2月26日 · Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management...

2014年7月24日 · For almost 10 years, the main goal of the treatment of CML with tyrosine kinase inhibitors (TKIs) has been the achievement of the so-called “major molecular response” (MMR; …

2018年11月30日 · Quantitative PCR assays of peripheral blood, measuring the level of BCR-ABL1 messenger RNA relative to an internal control gene, are the gold standard for monitoring …

2020年3月3日 · Achieving an MMR (BCR-ABL1 ≤ 0.1%) predicts a CML-specific survival close to 100% as disease progression is uncommon once this level of cytoreduction has been achieved.

Since the introduction of the drug Gleevec® and similar tyrosine kinase inhibitors, the number of patients with chronic myeloid leukemia (CML) who enter remission and stay in remission for …

2023年4月24日 · In this review, we discuss these issues to clarify questions about the management of CML in frontline and post-frontline TKI failure settings. The primary aim of …

A major molecular response (MMR) means that the amount of BCR-ABL gene in your blood or bone marrow is 1/1000 th (or less) of what's expected in someone with untreated CML. You …

2012年3月3日 · Chronic myeloid leukemia (CML) affects 1 to 2 people per 100,000 annually, with an estimated 5,000 patients diagnosed in the United States each year (Altekruse et al., 2009). …

2012年11月16日 · In order to describe the different treatments and factors involved in the first major molecular response (MMR) occurence in chronic phase CML, its maintenance, and its …

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation …